financetom
Business
financetom
/
Business
/
Abbott Laboratories Unusual Options Activity
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Abbott Laboratories Unusual Options Activity
Apr 11, 2024 12:02 PM

Whales with a lot of money to spend have taken a noticeably bullish stance on Abbott Laboratories ( ABT ).

Looking at options history for Abbott Laboratories ( ABT ) we detected 8 trades.

If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 50% with bearish.

From the overall spotted trades, 5 are puts, for a total amount of $190,983 and 3, calls, for a total amount of $136,877.

Predicted Price Range

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $92.5 to $115.0 for Abbott Laboratories ( ABT ) over the recent three months.

Volume & Open Interest Development

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.

This data can help you track the liquidity and interest for Abbott Laboratories's ( ABT ) options for a given strike price.

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Abbott Laboratories's ( ABT ) whale activity within a strike price range from $92.5 to $115.0 in the last 30 days.

Abbott Laboratories Option Activity Analysis: Last 30 Days

Significant Options Trades Detected:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
ABT PUT SWEEP BEARISH 11/15/24 $8.8 $8.6 $8.8 $115.00 $75.6K 179 86
ABT CALL TRADE BULLISH 06/21/24 $19.65 $19.25 $19.54 $92.50 $54.7K 42 0
ABT CALL TRADE NEUTRAL 11/15/24 $20.85 $18.4 $19.54 $95.00 $54.7K 12 0
ABT PUT SWEEP BULLISH 04/19/24 $4.8 $4.75 $4.74 $115.00 $31.7K 1.7K 410
ABT PUT TRADE BULLISH 05/17/24 $2.71 $2.67 $2.67 $110.00 $29.1K 1.7K 192

About Abbott Laboratories

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Current Position of Abbott Laboratories

Currently trading with a volume of 1,707,071, the ABT's price is up by 0.43%, now at $111.65.

RSI readings suggest the stock is currently may be approaching oversold.

Anticipated earnings release is in 6 days.

What Analysts Are Saying About Abbott Laboratories

A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $126.5.

Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Abbott Laboratories ( ABT ), targeting a price of $128.

An analyst from Evercore ISI Group has decided to maintain their Outperform rating on Abbott Laboratories ( ABT ), which currently sits at a price target of $125.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Abbott Laboratories ( ABT ) options trades with real-time alerts from Benzinga Pro.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US Supreme Court won't revive mumps vaccine antitrust case against Merck
US Supreme Court won't revive mumps vaccine antitrust case against Merck
Oct 20, 2025
* Plaintiffs say they overpaid for mumps vaccine for years * Suit alleges violations of federal and state laws By Mike Scarcella WASHINGTON, Oct 20 (Reuters) - The U.S. Supreme Court declined on Monday to hear a bid by a group of physicians and healthcare providers to revive their antitrust lawsuit accusing drugmaker Merck ( MRK ) of misleading federal...
Form 8.3 - American Axle & Manufacturing Holdings Inc.
Form 8.3 - American Axle & Manufacturing Holdings Inc.
Oct 20, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Polar Asset Management Partners Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Norwegian Cruise Line, Repsol Sign Long-Term Deal for Renewable Fuels Supply in Spain
Norwegian Cruise Line, Repsol Sign Long-Term Deal for Renewable Fuels Supply in Spain
Oct 20, 2025
09:53 AM EDT, 10/20/2025 (MT Newswires) -- Norwegian Cruise Line ( NCLH ) and Repsol said Monday they have signed an eight-year agreement for the supply of renewable marine fuels at the Port of Barcelona in Spain. Financial details were not provided. Starting in next year's European season, Repsol will provide renewable fuels, including biofuels and, from 2029, renewable methanol,...
Form 8.3 - Dowlais Group PLC
Form 8.3 - Dowlais Group PLC
Oct 20, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Polar Asset Management Partners Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved